OUR MISSION

Marizyme is an integrated life sciences company dedicated to the acquisition, development and commercialization of therapies, devices and related products that maintain cellular viability and support metabolism, thereby promoting cellular health and proper function.

 

LEARN MORE

PRODUCTS & PIPELINE

Marizyme’s Soma technology platform for targeting organ specific cells promotes cellular viability, integrity, structure, and function. Cardiovascular disease is the first targeted disease franchise.

 

Marizyme’s flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that minimizes endothelial cell damage, leading to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery.

 

LEARN MORE

INVESTORS

Loading data...

DuraGraft improves clinical outcomes by reducing the incidence and complications of graft failure